(Q37866755)

24 August 2017

1 reference

title

Telmisartan: a review of its use in cardiovascular disease prevention (English)

1 reference

24 August 2017

main subject

cardiovascular disease

1 reference

James E Frampton

1

1 reference

24 August 2017

publication date

1 April 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

71

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

651-677

1 reference

Cardiovascular disease risk factors: epidemiology and risk assessment.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Progression of cardiovascular damage: the role of renin-angiotensin system blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Renin-angiotensin system blockade and cardiovascular and renal protection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Telmisartan: a review of its use in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Telmisartan: a review of its use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Telmisartan: a different angiotensin II receptor blocker protecting a different population?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized,

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effect of 24-week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Angiotensin II receptor blocker telmisartan: effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

New standards in hypertension and cardiovascular risk management: focus on telmisartan

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effect of telmisartan on renal outcomes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Human C-peptide acutely lowers glomerular hyperfiltration and proteinuria in diabetic rats: a dose-response study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Telmisartan to prevent recurrent stroke and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Asse

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristi

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARG

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE i

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

21 January 2018

Lessons from ONTARGET.

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Ramipril: a review of its use in the prevention of cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Understanding the PRoFESS Study for Secondary Stroke Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Digestion of the antiplatelets comparison of PRoFESS: 18-7=1?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Next generation multifunctional angiotensin receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Safety of telmisartan in patients with arterial hypertension : an open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Focus on the ONTARGET results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

A New Option for Therapeutic Management of Patients with Cardiovascular Disease : A Closer Look at the ONTARGET Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Are the pleiotropic effects of telmisartan clinically relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206710-000000000-00000

Arterial stiffness and pharmacological interventions--the TRanscend arterial stiffNess Substudy (TRANS study).

21 January 2018

1 reference

12 December 2020

Clinical trial update: focus on the ONTARGET study

1 reference

12 December 2020

Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation.

1 reference

12 December 2020

Results of the ONTARGET and TRANSCEND studies: an update and discussion.

1 reference

12 December 2020

The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients

1 reference

12 December 2020

Angiotensin II receptor blockers

1 reference

12 December 2020

Effects of telmisartan on fat distribution in individuals with the metabolic syndrome

1 reference

12 December 2020

The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies

1 reference

12 December 2020

The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients

1 reference

12 December 2020

Telmisartan improves insulin resistance in patients with low cytokine levels

1 reference

12 December 2020

Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk

1 reference

12 December 2020

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

12 December 2020

Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes

1 reference

12 December 2020

Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome

1 reference

12 December 2020

The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients

1 reference

12 December 2020

Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Tria

1 reference

12 December 2020

ONTARGET still OFF-TARGET?

1 reference

12 December 2020

Angiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generation

1 reference

12 December 2020

Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers

1 reference

12 December 2020

Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway

1 reference

12 December 2020

Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.

1 reference

12 December 2020

Impact of Telmisartan Versus Ramipril on Renal Endothelial Function in Patients With Hypertension and Type 2 Diabetes

1 reference

12 December 2020

10.2165/11206710-000000000-00000

Identifiers

DOI

1 reference

24 August 2017

1 reference